Dr. Jan G. J. van de Winkel, Ph.D., is a Co-Founder of Genmab A/S. Dr. van de Winkel has been the Chief Executive Officer and President at Genmab A/S since June 15, 2010 and 2010 respectively. He served as the President of Research and Development at Genmab A/S. and served as its Chief Scientific Officer from June 1998 to 2010. He serves as an Advisor at AGLAIA BioMedical Ventures B.V. He is a Scientific Advisor to international venture capital firms. He has more than 20 years of experience in the therapeutic antibody field. He served as a Vice President and Scientific Director at Medarex Europe until 2000. In 1997, he set up a research unit for Genmab A/S. He holds a Professorship in Immunology at Utrecht University, The Netherlands. Dr. van de Winkel’s research focuses on the biological role and clinical application of antibodies. Within his laboratory clinical implications of Fc receptor heterogeneity and novel therapeutic strategies for cancer, autoimmune disorders and infectious diseases are studied. From 1992 to 1996, he was an Associate Professor at Utrecht University's Department of Experimental Immunology. From 1988 to 1992, he was a Post-Doctoral fellow at the Department of Experimental Immunology at Utrecht University, visiting Scientist at the Department of Internal Medicine of the Ohio State University and Assistant Professor at the Department of Experimental Immunology at Utrecht University. He serves as a Member of Scientific Advisory Board of Thuja Capital Healthcare Fund I, Thuja Capital Management B.V., and Biotechnology Turnaround Fund B.V. He serves as a Member of Life Sciences Advisory Board of Advent Venture Partners. He served as a Director of Forward Pharma A/S since August 12, 2014 until May 5, 2017. He serves as the Chairman of the Board of Directors of Regenesance and Member of the Board of Directors of ISA Pharmaceuticals and Celdara Medical and the Advisory Board of Capricorn Health-tech Fund. He is a Board Member of several biotech companies. He has been responsible for a number of patents and pending patent applications and is the author of over 300 scientific publications. He is one of the leading scientists in the study of antibodies and their interaction with the human immune system. Dr. van de Winkel is widely recognized, as one of the leading scientists in the study of antibodies and their interaction with the immune system and has been responsible for a number of patents and patent applications. His research is supported by grants from Utrecht University, The Dutch Cancer Foundation, The Netherlands Organization for Scientific Research and the National Rheumatism Foundation. He conducted postdoctoral work at the University Hospital Utrecht and Ohio State University, before returning to Utrecht University in 1991. He is a part-time Professor of Immunotherapy at the University Medical Center. Dr. van de Winkel received a Ph.D. in Immunology, with his thesis on Human monocyte Fc receptors, in 1988 and a M.Sc. degree in Biology in 1985 from the University of Nijmegen, The Netherlands.  

Infectious Disease